Confirmed and Durable Anticancer Activity in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients From Phase 1 Trial
NSCLC Data Featured in Proffered Presentation Session at Virtual ESMO 2020
Manuscript Represents First Phase 1 Results Published for a KRAS G12C Inhibitor
PR Newswire
THOUSAND OAKS, Calif., Sept. 20, 2020